Cinnarizine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Cinnarizine: From Vertigo / Motion Sickness to Migraine Disorder
One-Sentence Summary
Cinnarizine is a calcium channel blocker and H1-antihistamine historically used for vertigo, motion sickness, and vestibular disorders. The TxGNN model predicts it may be effective for migraine disorder prophylaxis, with 0 registered clinical trials and 20 supporting publications — including multiple RCTs and a 2022 systematic review with meta-analysis — currently backing this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Vertigo, motion sickness, vestibular disorders (no Singapore regulatory record available) |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 97.69% |
| Evidence Level | L2 |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data from DrugBank is currently unavailable. However, based on published pharmacological literature, cinnarizine acts through two complementary pathways: (1) blockade of L- and T-type voltage-gated calcium channels in cerebrovascular smooth muscle, which suppresses cortical spreading depression (CSD) — the electrophysiological substrate of migraine aura; and (2) H1 receptor antagonism, which attenuates histamine-mediated vasodilation implicated in migraine pathogenesis. This dual mechanism positions cinnarizine pharmacologically alongside established calcium channel blockers such as flunarizine (its difluorinated derivative), which is already approved for migraine prophylaxis in many countries.
Vertigo and migraine are closely linked neurological conditions sharing overlapping pathophysiology, including aberrant calcium channel function (CACNA1A mutations underlie both familial hemiplegic migraine and episodic ataxia), neurovascular dysregulation, and brainstem sensitisation. Cinnarizine's efficacy in the vestibular domain thus provides a mechanistically plausible bridge to migraine prophylaxis, particularly in patients where vestibular migraine overlaps with classical migraine.
The TxGNN prediction is further supported by a substantial clinical evidence base: the 2022 systematic review and meta-analysis (PMID 36148684) specifically evaluated cinnarizine's prophylactic effectiveness in migraine disorder, and multiple double-blind placebo-controlled RCTs — particularly in the paediatric population — have demonstrated significant reductions in headache frequency. Notably, cinnarizine is already referenced in certain regional neurology guidelines as an alternative prophylactic agent, particularly where flunarizine is unavailable or not registered.
Clinical Trial Evidence
Currently no related clinical trials registered on ClinicalTrials.gov or ICTRP for cinnarizine in migraine disorder.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39388181 | 2024 | Network Meta-analysis | JAMA Network Open | Evaluated pharmacological interventions for migraine prophylaxis in children and adolescents; assessed efficacy and safety across multiple agents including cinnarizine |
| 38641932 | 2024 | RCT | Cephalalgia | Double-blind RCT comparing cinnarizine vs. amitriptyline for paediatric migraine prophylaxis; cinnarizine arm showed significant reduction in headache frequency |
| 36148684 | 2022 | Systematic Review + Meta-analysis | Pain Practice | Synthesised available data on prophylactic effectiveness of cinnarizine in migraine disorder; confirmed preventive benefit across multiple studies |
| 37114310 | 2022 | RCT | Cellular and Molecular Biology | Semi-experimental RCT (n=120 adults) comparing propranolol + cinnarizine vs. propranolol + placebo in preventing acute migraine attacks |
| 31707814 | 2020 | RCT | Cephalalgia | Double-blind placebo-controlled RCT evaluating cinnarizine and sodium valproate for migraine prophylaxis in children and adolescents |
| 31413170 | 2019 | Clinical Practice Guideline | Neurology | AAN/AHS guideline update on pharmacologic treatment for paediatric migraine prevention; provides evidence-based context for available prophylactic agents |
| 25023977 | 2014 | RCT | Pediatric Neurology | Double-blind placebo-controlled RCT demonstrating efficacy and safety of cinnarizine (calcium channel blocker) in migraine prophylaxis in school-age children |
| 25709150 | 2014 | Clinical Study | Acta Otorhinolaryngologica Italica | Assessed combined cinnarizine + betahistine in Ménière's disease patients with and without migraine; observed benefit in migraineur subgroup |
| 24433203 | 2014 | Review | Headache | Reviewed the role of histamine as a neurotransmitter in migraine pathophysiology, supporting the rationale for H1-antagonism in migraine management |
| 25217187 | 2014 | Review | European Journal of Clinical Pharmacology | Assessed lactation risk of common anti-migraine drugs including cinnarizine; provides safety context for a specific population |
Singapore Market Information
Cinnarizine has no registered product licenses in Singapore. No approved indications, dosage forms, or authorisation numbers are available from the local regulatory database.
Safety Considerations
Please refer to the package insert for safety information.
Note: Singapore regulatory labelling (including warnings and contraindications) was not available at the time of this assessment (Data Gap). Clinicians should consult the originator package insert or international labelling (e.g., EU SmPC or equivalent). Known class effects of calcium channel blockers and H1-antihistamines — including sedation, weight gain, and extrapyramidal symptoms with long-term use — should be considered.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Cinnarizine has a mechanistically sound rationale for migraine prophylaxis through dual calcium channel blockade and H1-antagonism, supported by a 2022 systematic review and meta-analysis, multiple RCTs (particularly in the paediatric population), and a published narrative review specifically positioning it as an alternative prophylactic recommendation. The evidence level meets L2, and its close structural and pharmacological relationship to flunarizine — an approved migraine prophylactic — strengthens biological plausibility. The main limitations are the absence of Singapore registration, lack of a formal regulatory indication for migraine anywhere in the dataset, and missing local safety labelling.
To proceed, the following is needed:
- Obtain and review the full package insert (warnings, contraindications, drug interactions) from a recognised regulatory source (e.g., EMA, MHRA, or originator labelling)
- Confirm current availability and regulatory pathway in Singapore (off-label use policy or formal indication extension)
- Review long-term safety data, particularly risk of extrapyramidal symptoms and parkinsonism with prolonged use — a known concern with cinnarizine and flunarizine
- Conduct paediatric-specific risk-benefit assessment if use in children is intended, given that most RCT evidence is in the paediatric population
- Consider whether flunarizine (the registered analogue in many markets) would serve as a more appropriate reference product for regulatory comparison
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.